Detailed instructions for the dosage and usage of Cresflut

Crinecerfont, trade name Crenessity, is an innovative corticotropin-releasing factor 1 receptor antagonist, providing a groundbreaking management method for patients with classic congenital adrenal hyperplasia (CAH). As an adjunct to glucocorticoid replacement therapy, crisflutide reduces androgen levels in a more targeted manner, potentially allowing for a reduction in steroid dosage. This article will introduce in detail the safe use guidelines of Cresflutide in terms of indications, usage and dosage.

Crisflutide is mainly used to control androgen levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH). For children under 4 years old, its safety and effectiveness have not been confirmed, so its use is not recommended. Cresflutide is not a steroid, but it reduces the secretion of adrenocorticotropic hormone (ACTH) by inhibiting the corticotropin-releasing factor 1 receptor, thereby reducing the overproduction of androgens.

The dose of Cresflutide needs to be adjusted according to the patient's age and weight, as follows:

Adult patients: The recommended dose is 100 mg orally twice daily, taken in the morning and evening with food.

Pediatric Patients: Recommended Dosage Based on Weight:

10kgabove20kgbelow: twice a day, each time25mg;

20kgabove55kgbelow: twice a day, each time50mg;

55kgand above: 100mg twice a dayeach time.

If one or more doses are missed, patients are advised to take a missed dose as soon as possible (even if it is close to the next scheduled dose) and then resume their regular dosing schedule. To improve drug absorption and reduce gastrointestinal discomfort, it is recommended to take it with food.

The following are precautions to take during treatment with Cresflutide:

Continue glucocorticoid therapy: During treatment with crisflutide, patients should continue to receive glucocorticoid replacement therapy to avoid the risk of acute adrenal insufficiency or adrenal crisis. Corticosteroid dose adjustments should be made under physician supervision and should not be lower than those required for alternative therapy.

Assessment of Androstenedione Levels: Androstenedione levels can be assessed four weeks after initiation of crisflutide treatment to guide glucocorticoid dose adjustments.

Management of stress situations: In situations of increased cortisol demand, such as acute illness, severe trauma, or surgery, patients should receive stress doses of glucocorticoids.

Crisflutide provides a new treatment option for CAH patients by targeting the reduction of androgen levels, potentially reducing the dose of glucocorticoids. However, its use must strictly follow the recommended dosage and precautions and be conducted under the guidance of a doctor. For patients 4 years old and above CAH, crisflutide is a safe and effective adjuvant therapy, but it is necessary to pay close attention to adverse reactions and ensure the rational use of glucocorticoids. As more clinical data accumulates, Cresflut is expected to bring better therapeutic effects to more patients.xa0

Reference link: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218808s000,218820s000lbl.pdf